Letter

Efficacy should drive atypical antipsychotic treatment

BMJ 2003; 326 doi: 10.1136/bmj.326.7383.283/a (Published 1 February 2003)
Cite this as: BMJ 2003;326:283.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Leslie L Citrome (citrome@nki.rfmh.org), clinical professor of psychiatry
  1. Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA

    EDITOR—Koro et al say that olanzapine is associated with a clinically important and significant increased risk of diabetes.1 To date five other pharmacoepidemiological papers have been published about the possible increase in risk for diabetes in patients receiving atypical antipsychotics.2–6

    All use a variety of methods and have come up with a variety of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular